Trial
NCT03272464
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
Incyte Corporation
Condition
Melanoma
Intervention
Trametinib
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-22